Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. April 2025 16:00 ET | Quelle: Interpace Biosciences, Inc.

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace”...
29. Juli 2024 08:25 ET | Quelle: Interpace Biosciences, Inc.

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined...
30. April 2020 08:32 ET | Quelle: CMI

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market to surpass US$ 211.3 Mn globally by 2027, Says CMI

SEATTLE, April 30, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global methicillin resistant Staphylococcus aureus (MRSA) testing systems market is estimated to be valued at...